A new trading day began on Friday, with Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock price down -0.35% from the previous day of trading, before settling in for the closing price of $5.75. RXRX’s price has ranged from $3.79 to $12.36 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 112.62%. Meanwhile, its annual earnings per share averaged 5.03%. With a float of $305.89 million, this company’s outstanding shares have now reached $389.55 million.
In terms of profitability, gross margin is 10.66%, operating margin of -814.58%, and the pretax margin is -790.4%.
Recursion Pharmaceuticals Inc (RXRX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 23.91%, while institutional ownership is 60.03%. The most recent insider transaction that took place on Mar 27 ’25, was worth 836,987. In this transaction Chief Executive Officer of this company sold 138,574 shares at a rate of $6.04, taking the stock ownership to the 1,117,450 shares. Before that another transaction happened on Mar 27 ’25, when Company’s Officer proposed sale 138,574 for $6.04, making the entire transaction worth $836,987.
Recursion Pharmaceuticals Inc (RXRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.68% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Here are Recursion Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 39.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -1.37 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Looking closely at Recursion Pharmaceuticals Inc (NASDAQ: RXRX), its last 5-days average volume was 15.37 million, which is a drop from its year-to-date volume of 23.55 million. As of the previous 9 days, the stock’s Stochastic %D was 68.70%. Additionally, its Average True Range was 0.54.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 22.64%, which indicates a significant decrease from 83.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 128.27% in the past 14 days, which was higher than the 110.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.52, while its 200-day Moving Average is $6.87. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $5.87. Second resistance stands at $6.00. The third major resistance level sits at $6.17. If the price goes on to break the first support level at $5.57, it is likely to go to the next support level at $5.40. Now, if the price goes above the second support level, the third support stands at $5.27.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
With a market capitalization of 2.30 billion, the company has a total of 401,991K Shares Outstanding. Currently, annual sales are 58,840 K while annual income is -463,660 K. The company’s previous quarter sales were 4,550 K while its latest quarter income was -178,910 K.
